Msn Group News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Perplexed. Its a guy who is handpicking great content from around the world about the middle east to help explain it to normal people without all the hype. Thats a really big deal. That idea that that person is forming a new node in the web with a collection of all this great content. So for publishers its important to think about that. That person could be in this case of flipboard but they might be on facebook or twitter or all the above. Thats how the web works now. The research in august, the average u. S. Smart phones user downloaded zero apps per month. In a world, how do you reach new u...

CV Sales: November was a tepid month for commercial vehicle sales with just 2% growth compared to November 2022, and a 19% drop vs. October 2023. A few major trends have been driving sales in the CV industry this year. A combination of near-term challenges and opportunities will determine the growth of the industry in the last 4 months of the current financial year. while the short-term outlook may not be transparent, the long-term outlook for the CV segment looks strong. A combination of world class products, ongoing reforms, focus on infrastructure and the country’s growth will dri...

HYDERABAD: MSN Group, one of the fastest-growing, research-based, and fully integrated pharmaceutical companies based out of Hyderabad, India entered into a licencing agreement with Medicines Patent Pool (MPP) for manufacturing and distribution of a generic version of Pfizer’s oral COVID-19 treatment. The novel antiviral pill is a combination of nirmatrelvir and ritonavir

HYDERABAD: Hyderabad-based MSN Labs (MSN) on Thursday said it has entered into a royalty-free, non-exclusive, voluntary license agreement with US drug giant Eli Lilly & Co for manufacturing and marketing Covid-19 treatment drug Baricitinib in India. MSN said it will be launching the product under the brand name Baridoz in two strengths 2 mg & 4mg. The company has also developed the active pharmaceutical ingredient and the formulation of Baricitinib in its in-house R&D and manufacturing units, it said. The rheumatoid arthritis drug Baricitinib has been granted a restricted emergency use app...